This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Zynquista
  • /
  • A Phase 3 Study to Evaluate the Safety of Sotaglif...
Clinical trial

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone (inTandem3)

Read time: 2 mins
Last updated:1st Sep 2015
Identifier: NCT02531035

This Phase 3 study is designed to demonstrate the net benefit of sotagliflozin versus placebo in patients with T1D.

Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 1405 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes
Study Start Date: September 2015
Actual Primary Completion Date: April 2017
Actual Study Completion Date: April 2017

- Experimental:
Treatment A
Sotagliflozin (fasted conditions)
- Placebo Comparator: Treatment B
Placebo (fasted conditions)

Category Value
Date last updated at source 2017-12-26
Study type(s) Interventional
Expected enrolment 1405
Study start date 2015-09-01
Estimated primary completion date 2017-04-01

View full details